Emergent BioSolutions Inc. (EBS)
About Emergent BioSolutions Inc.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $742.9M
- Net income
- $52.6M
- Total assets
- $1.3B
- Market cap
- $416.4M
- Gross margin
- 56.1%
- Operating margin
- 13.5%
- Net margin
- 7.1%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $742.9M
- Cost of revenue
- $326.2M
- Gross profit
- $416.7M
- Operating expenses
- $316.6M
- Operating income
- $100.1M
- Income tax
- $30.2M
- Net income
- $52.6M
- EPS (basic)
- $0.98
- EPS (diluted)
- $0.93
Balance sheet
- Total assets
- $1.3B
- Current assets
- $662.5M
- Total liabilities
- $796.0M
- Current liabilities
- $132.2M
- Shareholders’ equity
- $522.6M
Cash flow
- Operating cash flow
- $170.6M
- Investing cash flow
- $69.4M
- Financing cash flow
- -$136.6M
- Net cash flow
- $103.5M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $416.4M
- P/E ratio
- 7.8
- EPS (diluted)
- $0.93
- Shares outstanding
- 57.4M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Nov 15, 2006
Emergent BioSolutions Inc. (EBS) Stock Price
- Profitable — net income of $52.6M in FY2025.
- Revenue declined 59% from FY2021 to FY2025.
- Gross margin of 56.1%, net margin 7.1%.
- Trading 48% below its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 7.8.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
Peers & competitors
No reviews yet. Be the first to review Emergent BioSolutions Inc..
Write a review
News about Emergent BioSolutions Inc.
News & sentiment via Polygon.io
Emergent BioSolutions Inc.: frequently asked questions
Is Emergent BioSolutions Inc. an American company?
Emergent BioSolutions Inc. is a US-based company headquartered in Gaithersburg, Maryland, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Emergent BioSolutions Inc. headquartered?
Emergent BioSolutions Inc. is headquartered in Gaithersburg, Maryland, United States.
Is Emergent BioSolutions Inc. publicly traded?
Yes — Emergent BioSolutions Inc. is a publicly traded company. Its stock trades under the ticker symbol EBS on the NYSE.
What does Emergent BioSolutions Inc. do?
Emergent BioSolutions Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
When was Emergent BioSolutions Inc. founded?
Emergent BioSolutions Inc. was founded in 1998.
